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Physician Assistants’ Views of Direct-to-Consumer Advertising Effects during 
Patient Encounters 
Abstract 
Purpose: Direct-to-consumer advertising (DTCA) has become an important tool for disseminating drug 
information that directly impacts the patients and providers in the delivery of health care. Limited research 
shows that DTCA has both benefits and drawbacks that impact public health. However, there is a paucity of 
empirical evidence of the effects of DTCA information discussed during an office visit from the perspective 
of physician assistants. The purpose of the study was to examine physician assistants’ general views 
of DTCA benefits and drawbacks, as well as the effects DTCA information discussed during patient 
encounters on physician assistant-patient relationship, physician assistants’ prescriptive authority and 
time efficiency of the visit. 
Methods: A cross-sectional design was used to survey physician assistants in a single U.S. Midwestern 
state. A random sample of 860 of the state’s 4,483 physician assistants was drawn. The final sample 
consisted of 161 PAs (18.72%). Of these, 149 PAs (93%) had experience with discussing DTCA during an 
office visit. Pearson’s chi-squared analysis, logistic regression and multinomial logistic regression analyses 
were used to measure the associations between the variables. 
Results: Of the 161 physician assistants, most thought that DTCA drove up drug costs (76%), promoted 
unnecessary fear of side effects (71%), and did not provide a balanced view of risks and benefits of the 
product (64%). Conversely, most agreed that DTCA alerted patients to new therapies (74%) and did not 
create a conflict between the physician assistant and supervising physician (71%). Of the 149 physician 
assistants who experienced discussion about DTCA during a visit, 49% reported that patients did so 
because they wanted a drug; 62% deemed patients’ requests inappropriate; and 74% viewed DTCA as 
worsening the time efficiency. Worsened efficiency was associated with the patient wanting a test, bringing 
a printed advertisement, and the advertisement not being relevant. Worsened physician assistant-patient 
relationship was associated with challenged authority. 
Conclusions: The study highlights the need to enhance dialogue between the physician assistant and the 
supervising physician about patient needs, to provide targeted DTCA educational training opportunities 
that sharpen communication and interpersonal skills, and to incorporate physician assistants’ 
perspectives in future guidelines governing DTCA. 
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ABSTRACT 
Purpose: Direct-to-consumer advertising (DTCA) has become an important tool for disseminating drug information that directly 
impacts the patients and providers in the delivery of health care. Limited research shows that DTCA has both benefits and 
drawbacks that impact public health. However, there is a paucity of empirical evidence of the effects of DTCA information discussed 
during an office visit from the perspective of physician assistants. The purpose of the study was to examine physician assistants’ 
general views of DTCA benefits and drawbacks, as well as the effects DTCA information discussed during patient encounters on 
physician assistant-patient relationship, physician assistants’ prescriptive authority and time efficiency of the visit. Methods: A 
cross-sectional design was used to survey physician assistants in a single U.S. Midwestern state. A random sample of 860 of the 
state’s 4,483 physician assistants was drawn. The final sample consisted of 161 PAs (18.72%). Of these, 149 PAs (93%) had 
experience with discussing DTCA during an office visit. Pearson’s chi-squared analysis, logistic regression and multinomial logistic 
regression analyses were used to measure the associations between the variables. Results: Of the 161 physician assistants, most 
thought that DTCA drove up drug costs (76%), promoted unnecessary fear of side effects (71%), and did not provide a balanced 
view of risks and benefits of the product (64%). Conversely, most agreed that DTCA alerted patients to new therapies (74%) and 
did not create a conflict between the physician assistant and supervising physician (71%). Of the 149 physician assistants who 
experienced discussion about DTCA during a visit, 49% reported that patients did so because they wanted a drug; 62% deemed 
patients’ requests inappropriate; and 74% viewed DTCA as worsening the time efficiency. Worsened efficiency was associated 
with the patient wanting a test, bringing a printed advertisement, and the advertisement not being relevant. Worsened physician 
assistant-patient relationship was associated with challenged authority. Conclusions: The study highlights the need to enhance 
dialogue between the physician assistant and the supervising physician about patient needs, to provide targeted DTCA educational 
training opportunities that sharpen communication and interpersonal skills, and to incorporate physician assistants’ perspectives 
in future guidelines governing DTCA. 
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INTRODUCTION 
Direct-to-consumer advertising (DTCA) has become an important tool for disseminating drug information that directly affects the 
patients and providers in the delivery of health care.1-4 Since 2012, DTCA spending has increased by 62%, reaching 6.4 billion in 
2016.2 Proposals to completely ban DTCA have not been supported by policy makers; instead, the focus has been on 
regulation.1,3  Limited empirical evidence shows that DTCA has both benefits and drawbacks that impact public health.1 On one 
hand, DTCA was thought to empower  patients to voice their health concerns to providers and encourage patients to follow the 
doctor’s instructions.4,6,7 It also improved the provider-patient relationship and raised awareness of underdiagnosed and treatable 
conditions.4-6,8,10 On the other hand, DTCA was believed to provide limited information of the drug risks and limited a patient’s 
willingness for lifestyle changes.4,7,8 It also increased the time for the provider to explain DTCA information and increased patient 
dissatisfaction when not given a requested prescription.4,8,9 DTCA was also perceived to lead to increased drug costs.4,7,8  
 
Empirical research has also found that DTCA acted as a catalyst, influencing patients to seek information about a drug’s side 
effects, effectiveness, and appropriateness for use.11 Therefore, DTCA may present an opportunity for enhancing provider-patient 
communication, shared decision-making and relationship.11 Murray et al. found the following factors associated with an improved 
provider-patient relationship as a result of DTCA information discussed during a visit: feeling that the patient was taking 
responsibility for their health, perceiving the request as appropriate, and doing what the patient wanted.4 In a different study, 
improved advanced practice nurse prescriber-patient relationship was associated with factors, such as the patient not bringing 
printed material during the visit, not seeking a referral, seeking nurse’s opinion only, not challenging nurses’ authority, and taking 
responsibility for their health, as was with the nurse having enough time to discuss the information.10  It was hypothesized that: 
 
H1: DTCA information discussed during an office visit may be associated with the provider-patient relationship. 
 
Delbaere and Smith proposed that consumers who have no knowledge of prescription drugs learn from DTCA differently than 
those who have.12 Further, consumers process DTCA information differently depending on their perceptions of the effectiveness 
of advertisements.12 Moreover, consumers use what they learn from the advertisements in many different ways, some of which 
may be found inappropriate or irrational by health care providers, and challenge the providers’ prescriptive authority and 
expertise.12 Specifically, an intervention that was not clinically indicated, not doing what the patient wanted, and not knowing the 
patient well enough to have good communication were factors associated with the doctors more likely to feel their prescriptive 
authority had been challenged as well as with worsened time efficiency of the visit.4 Similar factors were found to be associated 
with advanced practice nurse prescribers’ challenged prescriptive authority, namely: the nurse not having enough time to discuss 
the information, knowing the patient well enough to have a good communication, believing that the increase in drug advertisements 
was a very bad thing, and the patient not taking responsibility for their health.10 Hence, it was hypothesized that: 
 
H2: DTCA information discussed during an office visit may be associated with provider’s prescriptive authority being challenged. 
H3: DTCA information discussed during an office visit may be associated with the time efficiency of the visit. 
 
Research on the benefits and drawbacks of DTCA has been limited and mostly based on studies involving physicians.4,5,7 Few 
studies have also explored the specific effects of DTCA information discussed during patient encounters.4,10 The purpose of the 
study was to examine physician assistants’ general views of DTCA benefits and drawbacks. It is also the first study to test the 
effects of DTCA information discussed during patient encounters on physician assistant-patient relationship, physician assistants’ 
prescriptive authority and time efficiency of the visit. DTCA has continued to grow over the years and has the potential to influence 
providers, including physicians, physician assistants, and nurse practitioners. Hence, it is important to examine data reflective of 
diverse provider practices and experiences to inform the ongoing policy debate and research surrounding DTCA.  
 
METHODS 
Sampling and Data Collection  
This study uses a cross-sectional survey design. The target population for this study consists of PAs who hold a current license in 
the state. Data on the names and addresses of PAs were obtained from the Department of Safety and Professional Services. A 
sample of 860 participants was drawn from the population of 4,483 physician assistants (confidence interval [CI]: 95%; margin of 
error: ±2.7, 50% confidence). Of the 860 surveys that were delivered, 136 were returned by mail and 39 were completed online 
for a total of 175 (20.35%). Fourteen surveys were excluded from data analysis for the following reasons: declined to participate, 
incomplete or the PAs had either retired, or no longer practiced as PAs. The final study sample consisted of 161 participants for a 
usable response rate of 18.72%. Of these, 149 PAs had experience with DTCA discussion with a patient during an office visit 
during the last 12 months.  
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The study was approved by the Institutional Review Board at the investigator’s university. A mixed mode of mail and online data 
collection approach was used.13 The data collection procedures include: 1) sending a pre-notice letter, 2) mailing a cover 
letter/survey a week later, 3) following up with a reminder postcard one week after mailing survey, and 4) following up with a 
reminder card two weeks after the mailing of the first postcard. In the cover letter, PAs were assured complete anonymity; that 
participation was voluntary; that they could also complete the survey online, using the Qualtrics system; and that they might request 
an executive summary of the study.  
 
Instruments and Measures 
Likert-type questions (1 = Strongly Disagree; 5 = Strongly Agree) regarding DTCA benefits and drawbacks were adopted from a 
previously tested instrument and the literature review.4,7,10 The instrument was assumed to have content validity and reliability.7 In 
addition, questions were adopted from previous research to test the relationships between the dependent and independent 
variables.4,10 The independent variables, measured with closed-ended questions (1=Yes; 2=No), included whether the patient 
brought a printed advertisement material; the reason the patient talked to the PA in relation to the advertisement: wanted a test, 
wanted a particular drug, wanted a referral to specialist, wanted PA’s opinion only, wanted a prescription drug change; whether 
the PA did what the patient wanted; whether the PA felt the patient’s request was inappropriate for their health; whether the PA felt 
the patient was challenging his/her prescriptive authority/expertise; whether the patient was taking responsibility for their health; 
and whether the PA did not know the patient well enough to have a good communication. Additional independent variables were 
measured on a Likert scale (1=Not at All; 5=To a Great Extent) and included whether the DTCA information was relevant to the 
patient’s disease; whether the DTCA information was accurate enough; and the extent to which the PA met this patient’s information 
needs. The dependent variables used in this particular study included: PAs’ views of whether the patient bringing DTCA information 
to a visit affected the physician assistant-patient relationship (1 = Worsened Much; 5 = Improved Much); PAs’ views of whether 
the patient bringing DTCA information to a visit affected the time efficiency of the visit (1 = Worsened Much; 5 = Improved Much); 
and PAs’ feelings of whether their prescriptive authority/expertise has been challenged (1=Yes; 2=No).The survey also collected 
data on PAs’ demographic and practice-related characteristics.  
 
Statistical Analyses 
Descriptive statistics analysis (frequencies) was carried out, using Stata/IC 12.1 of StataCorp LP of all variables. Pearson’s chi-
squared analysis, logistic regression and multinomial logistic regression analyses were used to measure the associations between 
the dependent and independent variables. Prior to analysis, those variables were recoded 0, 1 (No/Yes respectively), while the 
Likert-scale categories were collapsed to three. For the binary independent variables, the odds ratios and percentage change in 
odds were interpreted directly. For independent variables that were not binary, the odds ratio for a 1-standard-deviation change in 
the predictor and percentage change in odds were used.14 
 
The associations between dependent variables ‘PA-patient relationship’ and ‘time efficiency of the visit’ and the independent 
variables were investigated using multinomial logistic regression. Multinomial logistics regression coefficients and 95% confidence 
intervals were reported. Since the parameter estimates are relative to the referent group (improved/improved much), the standard 
interpretation of the multinomial logit is that for a unit change in the independent variable, the logit of an outcome relative to the 
referent group is expected to change by its respective parameter estimate given the variables in the model are held constant.15 
The relative risk ratio (RRR) coefficients were also reported. These indicate how the risk of the outcome falling in the comparison 
group compared to the risk of the outcome falling in the referent group changes with the variable in question.13 Diagnostic tests 
were conducted to assess for multicollinearity, specification errors, influential observations, and model specification. Diagnostic 
analysis showed no violation of the logistic regression assumptions. For the multinomial logistic regression models, model fit 
statistics was performed and was satisfactory.  
 
RESULTS 
Participants’ Demographic and Practice Characteristics 
Table 1 presented descriptive statistics of participants’ demographic and practice characteristics. The 161 PAs were predominantly 
white (81%), female (71%), and 31% were between the ages of 20-39. Twenty-seven percent of PAs had more than 20 years of 
practice as a PA. The respondents had the following job specialties: family/general practice (37%), general surgery (3%), internal 
medicine (10%), emergency medicine (14%), pediatrics (3%) and other specialties (34%). More than half of the PAs practiced 
predominantly in clinics (58%). Forty-four percent of PAs reported seeing between 40-59 patients per week and spent between 
17-24 minutes per patient (55%).  
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Table 1. Demographic and Practice Characteristics of Respondents (N = 161) 
 N (%) 
Gender  
    Men 23.60 (38) 
    Women 70.81 (114) 
    Other 5.59 (9) 
Age Group  
<20 2.48 (4) 
20-39 31.06 (50) 
40-49 17.39 (28) 
50-59 21.74 (35) 
60> 27.33 (44) 
Ethnicity/Race  
White 81.37 (131) 
African American 5.59 (9) 
Hispanic 6.21 (10) 
Asian American/Pacific Islander 3.73 (6) 
American Indian 1.24 (2) 
Other Race 1.86 (3) 
Years of Practice as Physician Assistant  
<1 5.59 (9) 
1-4 18.01 (29) 
5-9 13.66 (22) 
10-14 26.09 (42) 
15-19 9.32 (15) 
20> 27.33 (44) 
Specialty  
Family/General 37.27 (60) 
General Surgery 3.11 (5) 
Internal Medicine 9.94 (16) 
Emergency Medicine 13.66 (22) 
Pediatrics 2.48 (4) 
Other 33.54 (54) 
Setting  
Clinic 57.76 (93) 
Hospital 27.33 (44) 
Physician Office 7.45 (12) 
Long-term Care 3.11 (5) 
Correction Institution 1.86 (3) 
Other 2.48 (4) 
Number of Patients Seen Per Week  
<20 6.83 (11) 
20-29 7.45 (12) 
30-39 13.66 (22) 
40-49 26.09 (42) 
50-59 18.01 (29) 
60> 27.95 (45) 
Minutes Spent with Each Patient  
<9 2.48 (4) 
10-12 11.18 (18) 
13-16 18.63 (30) 
17-20 36.02 (58) 
21-24 18.63 (30) 
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Perceptions of DTCA Benefits and Drawbacks 
The descriptive statistics in Table 2 indicated that of all respondents (N = 161), most PAs thought that DTCA drove up the costs of 
prescription drugs 76% (95% CI, 73.3 to 78.7%), promoted unnecessary fear of side effects 71% (95% CI,  68.3 to 73.7%), did not 
provide a balanced  view of risks and benefits 64% (95% CI,  61.3 to 66.7%), did not promote PA-supervising physician 
communication 52% (95% CI, 49.3 to 54.7%), and often mislead patients 53% (95% CI, 50.3 to 55.7%). On the other hand, most 
PAs agreed that DTCA alerted patients to new therapies (74%, 95% CI, 71.3 to 76.7%) and did not create a conflict between the 
PA and the supervising physician 71% (95% CI, 68.3 to 73.7%). PAs were divided on issues, such as DTCA promoting PA-patient 
communication and giving patients confidence to talk to their PA.  
 
Table 2. Physician Assistant Views of the Effects of Direct-to-Consumer Advertising (N = 161) 
 
 
Direct-to-Consumer Drug Advertising: 
Disagree/Strongly 
Disagree 
% (n) 
Neutral 
 
% (n) 
Agree/Strongly 
Agree 
% (n) 
1. drives up the costs of prescription drugs 10.56 (17)        13.04 (21)     76.40 (123)    
2. gives patients confidence to talk to their PA about their 
concerns 
17.39 (28) 40.37 (65)     42.24 (68) 
3. interferes with good relationships between PAs and 
patients 
32.92 (53)        37.89 (61)    29.19 (47)        
4. promotes unnecessary visits to the PA’s office 36.02 (58) 37.27 (60)    26.71 (43) 
5. encourages patients to follow treatment instructions or 
advice from their PA 
27.95 (45) 44.1 (71) 27.95 (45) 
6. causes patients to take up more of their PA’s time 21.74 (35) 30.43 (49)      47.83 (77)        
7. improves patients’ understanding of medical conditions 
and treatments 
39.75 (64) 28.57 (46)      31.68 (51) 
8. promotes unnecessary fear of side effects 16.15 (26)        12.42 (20)       71.43 (115) 
9. helps patients get treatments they would not otherwise 
get 
44.10 (71) 24.84 (40)     31.06 (50)    
10. discourages the use of generic products 28.57 (46) 21.74 (35)         49.69 (80) 
11. alerts patients to new therapies 6.21 (10) 19.88 (32)      73.91 (119) 
12. pressures PAs to prescribe drugs they might not 
ordinarily prescribe 
39.75 (64)        25.47 (41)           34.78 (56)        
13. often misleads patients 19.25 (31)    23.60 (38)    57.14 (92) 
14. promotes PA-patient communication 21.74 (35) 39.13 (63)      39.13 (63)   
15. promotes compliance with patient’s treatment 
regimens 
38.51 (62) 37.27 (60)     24.22 (39) 
16. presents a balanced view of risks and benefits of the 
product 
63.98 (103) 27.33 (44)       8.70 (14) 
17. bias patients in favor of physicians over PAs 48.45 (78) 40.99 (66)     10.56 (17) 
18. should have stricter regulation 29.81 (48) 25.47 (41)     44.72 (72) 
19. promotes PA-supervising physician communication 51.55 (83) 38.51 (62) 9.94 (16) 
20. creates a conflict between PA and supervising 
physician 
71.43 (115)        22.36 (36)     6.21 (10)    
 
Perceptions about DTCA Information Discussed in a Visit  
Respondents were asked about the last time a patient talked about information from a drug advertisement during a visit. Of the 
161 participants, 149 had experienced patients bringing information from DTCA to a visit in the previous 12 months or 92.6% of 
respondents. Patients did so because they wanted a particular drug (49%, 95% CI, 46.3 to 51.7%). However, 62% of PAs (95% 
CI, 59.3 to 64.7%) deemed patient’s request inappropriate. Most PAs reported that they did not do what the patient wanted; that 
they did have enough time to discuss the information; that they felt the patient was taking responsibility for their health; that the 
patient was not challenging their authority; that they knew the patient well enough to have good communication; that the patient’s 
request for clinical intervention was not appropriate; and that they met the patient’s information needs (see Table 2). Further, drug 
advertisements brought by the patient were reported as somewhat accurate and relevant. 
 
25> 13.04 (21) 
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Effect of DTCA Information Discussed on Provider-Patient Relationship  
Table 3 in the Appendices showed that most PAs (74%, 95% CI, 71.3 to 76.7%) thought that patients bringing in information from 
a drug advertisement did not change the PA-patient relationship; 21% (95% CI, 18.3 to 23.7%) thought that relationship 
‘improved/improved much;’ and 5% (95% CI, 2.3 to 7.7%) thought that it ‘worsened/worsened much.” The Pearson’s chi-squared 
analysis revealed that an ‘improved/improved much’ PA-patient relationship was more likely to be associated with the patient 
wanting a referral, the PA doing what the patient wanted, the patient taking responsibility for their health, the drug advertisement 
information being accurate, and the PA meeting patient’s information needs. Conversely, the patient challenging the PA’s 
prescriptive authority was associated with a deterioration of the relationship.  
 
The analysis of multinomial logistic regression showed that the relative risk for ‘no change’ in PA-patient relationship to an 
“improved/improved much” one would be expected to decrease when the patient wanted a particular drug (RRR 0.16; CI, 0.0 to 
0.8), the patient wanted a referral (RRR 0.21; CI, 0.1 to 0.9), the PA doing what the patient wanted (RRR 0.07; CI, 0.0 to 0.3), and 
the patient challenging the PA’s prescriptive authority (RRR 0.14; CI, 0.0 to 0.8). The relative risk for “no change” in PA-patient 
relationship to an “improved/improved much” one would be expected to increase if the PA knew the patient well enough to have 
good communication (RRR 5.90; CI, 1.2 to 28.1). The multinomial logistic regression model was statistically significant (Pseudo R-
squared .4326, p < .001). 
 
Effect of DTCA Information Discussed on Prescriptive Authority  
Only 12 % (95% CI, 9.35 to 14.7%) of the PAs felt that their authority had been challenged by the patient during the discussion 
DTCA information. The chi-squared analysis revealed that PAs were more likely to feel their authority had been challenged with 
the patient bringing a printed advertisement material (26% vs. 101%; 2 (1, N = 149) = 4.15; p < .05; Cramér’s V = 0.17); the patient 
wanting a particular drug (18% vs. 7%; 2 (1, N = 149) = 4.42; p < .05; Cramér’s V = 0.17), and when the relationship between the 
PA and the patient worsened/worsened much (57% vs. 7% vs. 19%; 2 (2, N = 149) = 14.77; p < .001; Cramér’s V = 0.32). 
Conversely, PAs were more likely to feel their authority had not been challenged when the PAs had enough time to discuss the 
DTCA information (92% vs. 74%; 2 (1, N = 149) = 8.01; p < .01; Cramér’s V = 0.23). The multinomial logistic regression model 
was not statistically significant. 
 
Effect of DTCA Information Discussed on the Time Efficiency of Visit  
Table 4 in the Appendices showed that more PAs viewed discussing information from a drug advertisement as worsening the time 
efficiency of the visit (74%; 95% CI, 71.3 to 76.7%), whereas 26% reported “no change” (95% CI, 23.3 to 28.7%). No respondents 
reported an “improved” or “improved much” efficiency.  
 
Pearson’s chi-squared analysis revealed that worsened time efficiency was more likely to occur with the patient bringing a printed 
advertisement material (95% vs. 710%; 2 (1, N = 149) = 4.93; p < .05; Cramér’s V = 0.18), the patient wanting a test (89% vs. 
70%; 2 (1, N = 149) = 4.27; p < .05; Cramér’s V = 0.17), and the advertisement not being relevant to the patient’s medical condition 
(88% vs. 80% vs. 50; 2 (2, N = 149) = 15.69; p < .001; Cramér’s V = 0.33). 
 
The analysis of multinomial logistic regression showed that the relative risk for “worsened/worsened much” time efficiency of the 
visit to “no change” in the efficiency would be expected to decrease when the advertisement information was relevant to the medical 
condition of the patient (RRR 0.45; CI, 0.2 to 0.9). Conversely, the relative risk for “worsened/worsened much” time efficiency of 
the visit to “no change” in the efficiency would be expected to increase when the patient wanted a test (RRR 5.37; CI, 1.1 to 25.8). 
The multinomial logistic regression model was statistically significant (Pseudo R-squared .2133, p < .01). 
 
CONCLUSIONS, RECOMMENDATIONS AND LIMITATIONS 
There has been a lack of empirical studies on how DTCA information discussed during an office visit affects PA’s practice and 
relationship with patients.4,10 Within the physician-PA relationship, PAs exercise autonomy in making decisions about patient 
treatment and provide a broad range of services, including writing prescriptions. This study found that 93% of PAs were likely to 
encounter patients who sought information as a result of DTCA, and that DTCA gave patients confidence to talk to their PAs about 
their concerns (42%) and promoted PA-patient communication (39%). On the other hand, increased prescription drug costs, 
promoting fear of side effects and misleading patients were some of the most commonly reported drawbacks of DTCA.  
 
The study also provided preliminary evidence that improved PA-patient relationship was more likely to occur when PAs did what 
patients wanted; when patients were taking responsibility for their health; when the DTCA information discussed was accurate; 
when PAs met patients’ information needs; and when PAs knew the patient well enough to have good communication. PAs were 
more likely to feel their prescriptive authority had been challenged when patients brought DTCA info to the visit; wanted a particular 
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drug, and when the PA-patient relationship had worsened. These findings were consistent with previous empirical studies.4,10 
Consistent with the findings of Murray et al, worsened time efficiency of the visit was more likely to occur with the patient bringing 
a printed advertisement material, the patient wanting a test, and the DTCA drug information not being relevant to the patient’s 
medical condition.4 Hooker et al determined that the total costs of a visit or the cost of an episode of an illness was more economical 
overall when the PA delivered similar care to that of the physician.16 This suggests that DTCA may negatively affect employers in 
terms of PAs taking more time to explain contradictory drug information or patients’ requests for unnecessary treatment options or 
drugs. 
 
Recommendations 
Overall, PAs had mixed feelings of DTCA benefits and risks, which was in line with prior research.1-9 The findings imply that PA 
input should be sought in the development of DTCA guidelines and legislation, because these providers are affected by DTCA. 
 
The findings also imply that PAs need enhanced awareness of DTCA information discussion effects during patient encounters. 
Emotional intelligence training could facilitate PAs to better understand their emotional responses to patients and how their 
emotions impact their prescribing, diagnostic actions and clinical decision-making.17,18 Arora et al. found that higher emotional 
intelligence was positively associated with doctor-patient relationship, increased empathy, teamwork and communication skills.18 
PAs can also take advantage of “self-awareness spiral curriculum,” which has been used for developing physician emotional 
intelligence competencies beyond the period of formal medical training.17 The spiral curriculum (self as a student; self as a member 
of the healthcare team; self as a doctor; and self as a teacher and leader) could be used for training and developing emotional 
intelligence competencies over time and address physician’s situational needs.17 This developmental approach implied the need 
for ongoing training and leadership developing beyond the period of formal medical training.17  Similar types of self-awareness 
training could be provided to PAs to meet their situational needs. Such training would allow them to gain insight about their 
emotional responses to patients who approach them about DTCA information and may reduce PAs feelings of their prescriptive 
authority/expertise being challenged.  
 
PAs also need to have the skills and training to effectively communicate DTCA information and negotiate appropriate treatment 
options. Parker et al. suggest that any communication skills training should be specific to the areas that PAs might find challenging 
to their specialty.19 When it comes to DTCA encounters, such training could involve both the PA and the supervising physician and 
focus, for example, on how to collaboratively devise a care plan that meets patients’ goals and expectations; how to explain 
conflicted/unclear drug information; how to negotiate appropriate treatment options and encourage patient compliance; how to 
discuss prescribing decisions and clinical interventions to minimize feelings of being pressured; and how to use DTCA information 
as a health promotion and educational tool. An external assessment of communication skills by trained peers was suggested as a 
first step in improving the standard of provider-patient communication.20  
 
Greater collaboration and communication between the PAs and their supervising physician about DTCA encounters cannot be 
understated. In this study, 52% of PAs noted that DTCA did not promote PA-supervising physician communication, but that it also 
did not create a conflict with the supervising physician (71%). These findings suggest the importance of the PA maintaining 
coordinated consultation with their supervising physician about specific DTCA requests made by the patient. Chuang et al. also 
found that PAs were able to communicate best when they had support from their supervising physicians and specialists, as well 
as a shared understanding about the patient treatment options.21 The results regarding worsened time efficiency of the visit may 
suggest that employers should consider training that teaches PAs how to navigate DTCA discussion during a visit to minimize the 
costs of an episode of an illness.16  
 
Limitations 
This study has a few limitations. First, as a cross-sectional study, causation cannot be ascertained. Second, despite efforts to 
increase the survey response rate by providing an opportunity for mailed and online survey completion and multiple mailings, the 
response rate was low and might suggest a response bias. It is possible that the PAs might have self-selected themselves based 
on experience or interest in the study; so, the findings might not be generalizable.11 The analysis of demographic and practice-
related characteristics, however, revealed that the sample studied was very similar to the 2017 AAPA census by specialty, practice, 
age, and geographic distribution.22 Third, the results were also collected from a single state. Although PAs’ participation in this 
study was evenly present from all regions of the state (Northeastern 23%; Northern 27%; Southeastern 19%; Southern 18%; 
Western 14%), generalization to other states is limited as PAs’ views might differ across markets.  
 
CONCLUSIONS 
This study extended prior research on PAs’ views of the DTCA benefits and drawbacks.9 It was also the first to report DTCA effects 
on the PA-patient relationship, prescriptive authority, and time efficiency of the visit. Findings showed that PAs viewed DTCA as 
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having both positive and negative effects on the patient, provider, and the health care system. To enhance the PA-patient 
relationship and the time efficiency of the visit, it may be important to enhance dialogue between the PAs and their supervising 
physicians about patient needs and provide targeted training that sharpens PAs’ communication, interpersonal skills, and emotional 
intelligence skills during DTCA encounters. It is also important to incorporate PAs’ perspectives in the development of guidelines 
governing DTCA. Future research should replicate this study on a national level and also incorporate qualitative questions that 
solicit information of PA training and developmental needs to better handle DTCA requests. 
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Table 3. Factors Affecting Physician Assistant-Patient Relationship during Discussion about DTCA (N = 149) 
Independent Variables  
 
 
 
 
 
 
 
% (n) 
Dependent Variable: Physician Assistant-Patient Relationship 
 
 
Pearson’s Chi-Square 
Multinomial Logistic Regression 
LR chi2(30): 90. 97***; Pseudo R2: 0.4326 
IMP (Reference Group) 
W NC 
% (n) 
5.4 (8) 
W 
% (n) 
73.8 (110) 
NC 
% (n) 
20.8 (31) 
IMP 
χ2(df) p 
V 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
Did the patient bring printed ad material? 
Yes 
No 
 
12.8 (19) 
87.3 (130) 
 
10.53 
4.62       
 
57.89   
76.15           
 
31.58 
19.23 
 
3.04(2) 
0.14 
 
1.62 
 
 
5.07    
 
-0.84    
 
0.43    
Did the patient want a test? 
Yes 
No 
 
18.8 (28) 
81.2 (121) 
 
10.71   
4.13     
 
71.43 
74.38             
 
17.86 
21.49 
 
2.0(2) 
0.12 
 
0.52 
 
 
1.68    
 
1.04    
 
2.83 
Did the patient want a particular drug?  
Yes 
No 
 
48.99 (73) 
51.01 (76) 
 
5.48   
5.26       
 
68.49   
78.95           
 
26.03 
15.79      
 
2.4(2) 
0.13 
 
-18.02 
 
1.49 
-1.86* 
(-3.4 - -0.3) 
0.16 
(0.0 - 0.8) 
Did the patient want a referral? 
Yes 
No 
 
14.8 (22) 
85.2 (127) 
 
18.18 
3.15       
 
50.00  
77.95            
 
31.82 
18.90       
 
11.38(2)** 
0.28 
 
17.62 
 
 
4.51 
-1.55* 
(-3.0 - -0.1) 
0.21 
(0.1 - 0.9) 
Did the patient want a drug change? 
Yes 
No 
 
14.8 (22) 
85.2 (127) 
 
0.00  
6.30       
 
63.64 
75.59             
 
36.36 
18.11       
 
4.76(2) 
0.18 
 
-17.53 
 
2.43 
 
-1.27    
 
0.28    
Did the patient want your opinion only? 
Yes 
No 
 
55.03 (82) 
44.97 (67) 
 
6.10    
4.48       
 
76.83 
70.15             
 
17.07 
25.37     
 
1. 62(2) 
0.10 
 
0.75 
 
2.12    
 
-0.30 
 
0.74     
Did you do what the patient wanted? 
Yes 
No 
 
40.9 (61) 
59.1 (88) 
 
6.56   
4.55       
 
59.02  
84.09            
 
34.43 
11.36     
 
12.55(2)** 
0.29 
 
20.79    
 
1.06 
-2.72*** 
(-4.3 - -1.1) 
0.07 
(0.0 - 0.3) 
Did you have enough time to discuss the ad 
information? 
Yes 
No 
 
 
76.5 (114) 
23.5 (35) 
 
 
4.39 
8.57       
 
 
71.93  
80.00            
 
 
23.68 
11.43        
 
 
3.04(2) 
0.14 
 
 
19.54    
 
 
3.07 
 
 
-0.86    
 
 
0.42    
Did you feel the patient was taking 
responsibility for their health? 
Yes 
 
 
83.2 (124) 
 
 
6.45  
 
 
69.35 
 
 
24.19 
 
 
7.69(2)* 
 
 
39.56    
 
 
1.52 
 
 
-2.20    
 
 
0.11    
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No 16.8 (25) 0.00       96.00              4.00       0.23 
Table 3. Factors Affecting Physician Assistant-Patient Relationship during Discussion about DTCA (N = 149) (Continued) 
Independent Variables  
 
 
 
 
 
 
% (n) 
Dependent Variable: Physician Assistant-Patient Relationship 
 
Pearson’s Chi-Square 
Multinomial Logistic Regression 
LR chi2(30): 90. 97***; Pseudo R2: 0.4326 
IMP (Referent Group) 
W NC 
% (n) 
5.4 (8) 
W 
% (n) 
73.8 (110) 
NC 
% (n) 
20.8 (31) 
IMP 
χ2(df) p 
V 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
Did you think that the patient’s request was not 
appropriate for their health? 
Yes, not appropriate 
No, appropriate 
 
 
37.6 (56) 
62.4 (93) 
 
 
8.93    
3.23       
 
 
78.57 
70.97             
 
 
12.50 
25.81     
 
 
5.37(2) 
0.19 
 
 
23.67 
 
 
1.91 
 
 
-0.51 
 
 
0.60    
Did you feel the patient was challenging your 
prescriptive authority/expertise? 
Yes 
No 
 
 
12.1 (18) 
87.9 (131) 
 
 
22.22  
3.05       
 
 
44.44 
77.86            
 
 
33.33 
19.08      
 
14.77(2) 
*** 
0.32 
 
 
19.64 
 
 
3.42 
 
-1.96*   
   (-3.7- -0.3)  
 
0.14    
(0.0 - 0.8) 
Did you feel you did not know the patient well 
enough to have good communication? 
Yes 
No 
 
 
 
26.2 (39) 
73.8 (110) 
 
 
 
10.26  
3.64       
 
 
 
79.49  
71.82            
 
 
 
10.26 
24.55      
 
 
 
5.41(2) 
0.19 
 
 
 
0.12    
 
 
 
1.13    
 
 
 
1.77* 
(0.2-3.3) 
 
 
 
5.90   
(1.2-28.1) 
How relevant to patient’s medical condition was 
the information in the ad? 
Not very/Not at all 
Somewhat 
Very/To a great extent 
 
 
21.5 (32) 
  53.0 (79) 
25.5 (38) 
 
 
9.38  
5.06   
2.63       
 
 
78.13   
77.22   
63.16               
 
 
12.50 
17.72  
34.21          
 
 
6.99(4) 
0.15 
 
 
-4.57     
 
 
.01    
 
 
-0.23    
 
 
0.79    
How accurate was the ad information? 
Not very/Not at all 
Somewhat 
Very/To a great extent 
 
30.9 (46) 
57.7 (86) 
11.4 (17) 
 
8.70 
2.33 
11.76       
 
82.61   
72.09  
58.82                 
 
8.70 
25.58 
29.41               
 
 
9.55(4)* 
0.18 
 
2.54    
 
12.65    
 
-0.47      
 
0.62    
To what extent did you meet patient’s 
information needs? 
Not very/Not at all 
Somewhat 
Very/To a great extent 
 
 
4.0 (6) 
32.2 (48) 
  63.8 (95) 
 
 
0.00 
12.50 
2.11             
 
 
100.00   
70.83     
73.68        
 
 
0.00 
16.67   
24.21            
 
9.54(4)* 
0.18 
 
 
-21.26    
 
 
5.83 
 
 
0.12    
 
 
1.13    
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χ2 (df) P = Chi-squared (degrees of freedom) p value; V = Cramér’s V; *p< .05; **p < .01; ***p< .001; Coef.=The estimated multinomial logistic regression coefficient; 
RRR=Relative risk ratio for multinomial logit model; LR chi2=Likelihood Ratio Chi-Square; Pseudo R2=McFadden’s pseudo R-squared; W=worsened/worsened much; NC=no 
change, IMP=improved/improved much; CI=confidence interval. 
 
Table 4 Effects of DTCA on Time Efficiency of Visit: Chi-Squared Analysis and Multinomial Logistic Regression (N = 149) 
Independent Variables  
 
 
 
 
% (n)  
 
Dependent Variable:  
Time Efficiency of Visit 
Time Efficiency of Visit 
LR chi2(16): 36.06**; Pseudo R2: 0.2113 
NC (Reference Group) 
W 
% (n) 
73.8 (110) 
W 
% (n) 
26.2 (39) 
NC 
 
χ2(df) p 
V 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
Did the patient bring printed ad material? 
Yes 
No 
 
12.8 (19) 
87.3 (130) 
 
94.74 
70.77 
 
5.26  
29.23 
 
4.93 (1)* 
0.18 
 
1.79    
 
6.03    
Did the patient want a test? 
Yes 
No 
 
18.8 (28) 
81.2 (121) 
 
89.29 
70.25 
 
10.71 
29.75 
 
4.27 (1)* 
0.17 
 
1.68*    
(0.1-3.3) 
 
5.37   
(1.1-25.8)  
Did the patient want a particular drug?  
Yes 
No 
 
48.99 (73) 
51.01 (76) 
 
71.23 
76.32 
 
28.77 
23.68 
 
0.498 (1) 
-0.06 
 
-0.29    
 
0.75    
Did the patient want a referral? 
Yes 
No 
 
14.8 (22) 
85.2 (127) 
 
86.36 
71.65 
 
13.64 
28.35 
 
2.099 (1) 
0.12 
 
1.33    
 
3.79    
Did the patient want a drug change? 
Yes 
No 
 
14.8 (22) 
85.2 (127) 
 
77.27 
73.23 
 
22.73 
26.77 
 
0.16 (1) 
0.03 
 
0.80    
 
2.23     
Did the patient want your opinion only? 
Yes 
No 
 
55.03 (82) 
44.97 (67) 
 
74.39 
73.13 
 
25.61 
26.87 
 
0.03(1) 
0.01 
 
0.23    
 
1.25    
Did you do what the patient wanted? 
Yes 
No 
 
40.9 (61) 
59.1 (88) 
 
70.49       
76.14 
 
29.51 
23.86 
 
0.59(1) 
-0.06 
 
-0.55    
 
0.58    
Did you have enough time to discuss the ad 
information? 
Yes 
No 
 
 
76.5 (114) 
23.5 (35) 
 
 
70.18 
85.71 
 
 
29.82 
14.29 
 
 
3.35(1) 
-0.15 
 
 
-0.73    
 
 
0.48    
Did you feel the patient was taking responsibility for 
their health? 
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Yes 
No 
83.2 (124) 
16.8 (25) 
72.58 
80.00 
27.42 
20.00 
0.59(1) 
-0.06 
0.12    1.12    
 
Table 4 Effects of DTCA on Time Efficiency of Visit: Chi-Squared Analysis and Multinomial Logistic Regression (N = 149) (Continued) 
Independent Variables  
 
 
 
 
% (n)  
 
Dependent Variable:  
Time Efficiency of Visit 
Time Efficiency of Visit 
LR chi2(16): 36.06**; Pseudo R2: 0.2113 
NC (Reference Group) 
W 
% (n) 
73.8 (110) 
W/WM 
% (n) 
26.2 (39) 
NC 
 
χ2(df) p 
V 
 
Coef 
(95% CI) 
 
RRR 
(95% CI) 
Did you think that the patient’s request was not 
appropriate for their health? 
Yes, not appropriate 
No, appropriate 
 
 
37.6 (56) 
62.4 (93) 
 
 
75.00       
73.12       
 
 
25.00 
26.88 
 
 
0.06(1) 
0.02 
 
 
-0.77    
 
 
0.46    
Did you feel the patient was challenging your 
prescriptive authority/expertise? 
Yes 
No 
 
 
12.1 (18) 
87.9 (131) 
 
 
83.33       
72.52            
 
 
16.67 
27.48               
 
 
0.96(1) 
0.08 
 
 
0.37    
 
 
1.45    
Did you feel you did not know the patient well enough 
to have good communication? 
Yes 
No 
 
 
26.2 (39) 
73.8 (110) 
 
 
84.62       
70.00       
 
 
15.38 
30.00       
 
 
3.18(1) 
0.15 
 
 
0.79    
 
 
2.22    
How relevant to patient’s medical condition was the 
information in the ad? 
Not very/Not at all 
Somewhat 
Very/To a great extent 
 
 
21.5 (32) 
  53.0 (79) 
25.5 (38) 
 
 
87.50 
79.75 
50.00             
 
 
12.50 
20.25 
50.00                      
 
 
15.69(4)*** 
0.33 
 
 
-0.81*    
(-1.5 - -0.1) 
 
 
0.45    
(0.2-0.9) 
How accurate was the ad information? 
Not very/Not at all 
Somewhat 
Very/To a great extent 
 
30.9 (46) 
57.7 (86) 
11.4 (17) 
 
84.78       
68.60 
70.59       
 
15.22 
31.40 
29.41                     
 
4.16(4) 
0.17 
 
 
0.04       
 
 
1.04    
How did the patient bringing in a drug ad information 
affect PA-patient relationship 
Worsened/Worsened Much 
No Change 
Improved/Improved Much 
 
 
5.4 (8) 
73.8 (110) 
20.8 (31) 
 
 
100.00       
75.45  
61.29            
 
 
0.00 
24.55 
38.71 
 
 
5.51(4) 
0.19 
 
 
-0.62    
 
 
0.54     
To what extent did you meet patient’s info needs? 
Not very/Not at all 
 
4.0 (6) 
 
66.67 
 
33.33 
 
4.93(4) 
 
-0.66 
 
0.51 
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Somewhat 
Very/To a great extent 
32.2 (48) 
63.8 (95) 
85.42 
68.42 
14.58 
31.58 
0.18 
χ2 (df) P = Chi-squared (degrees of freedom) p value; *p< .05; **p < .01; ***p< .001; V = Cramér’s V. Coef. =The estimated multinomial logistic regression coefficient; 
RRR=Relative risk ratio for multinomial logit model. W=worsened/worsened much; NC=No change. CI = confidence interval. 
